Sudarshan Pharma Industries Q2 Results FY27: PAT Jumps 86.12% to Rs 7.78 Cr, Revenue Rs 216.97 Cr, PAT Rs 7.78 Cr

Sudarshan Pharma Industries Ltd (SUDARSHAN) Q2 Results FY27 announced on 29 October 2026, covering the company's financial performance for the July to September quarter. The results date brings consolidated revenue of Rs 216.97 Cr and PAT of Rs 7.78 Cr. Sudarshan Pharma Industries Q2 Results FY27 are reported on a consolidated basis, so these consolidated results are the figures used throughout this article.

This results analysis of Sudarshan Pharma Industries Q2 Results covers the financial highlights, business drivers, outlook and risks. It begins with the Financial Highlights table below, and the Univest Screener lists the same quarterly numbers for readers who follow NSE and BSE listed companies.

Click Here – Get Free Investment Predictions

Sudarshan Pharma Industries Q2 Results FY27: Financial Highlights

Metric	Q2 FY27 (Sep 26)	Q2 FY26 (Sep 25)	YoY Change
Revenue	Rs 216.97 Cr	Rs 168.87 Cr	+28.48% YoY
Net Profit (PAT)	Rs 7.78 Cr	Rs 4.18 Cr	+86.12% YoY

Source: company filing for Sudarshan Pharma Industries Q2 Results FY27, 29 October 2026. Figures in Rs Crore, Consolidated basis.

Key Takeaways from Sudarshan Pharma Industries Q2 Results: What Stands Out

• Revenue of Rs 216.97 Cr was up 28.48% YoY from Rs 168.87 Cr, which is the headline YoY growth figure for this quarter.
• Net profit of Rs 7.78 Cr rose 86.12% YoY from Rs 4.18 Cr, a gain that comfortably outpaced the rise in revenue.
• Net profit margin improved to 3.6% from 2.5% in the comparison quarter, so profit per rupee of sales increased.
• Sudarshan Pharma Industries Q2 Results FY27 also show return on equity of 16.74% in FY26 and debt of 1.87 times total assets in FY26.
• Performance analysis comes next: the following section explains how revenue, net profit and margin moved together this quarter.

Sudarshan Pharma Industries Q2 Results FY27: Performance Analysis

The numbers show net profit growing faster than revenue. Revenue reached Rs 216.97 Cr against Rs 168.87 Cr a year earlier, a rise of 28.48%, while net profit reached Rs 7.78 Cr against Rs 4.18 Cr, a rise of 86.12%. This results analysis therefore centres on how profit outpaced sales in the quarter.

Sudarshan Pharma Industries Q2 Results FY27 show net profit margin moving to 3.6% from 2.5% a year earlier, which means each rupee of revenue carried more profit than in the comparison quarter. The consolidated figures give a YoY growth picture for both the top line and the bottom line, and the same pair is worth tracking in coming filings.

Sudarshan Pharma Industries Q2 Results also sit inside the range of Rs 4.18 Cr to Rs 10.73 Cr of net profit seen across the last 5 quarters, so the latest Rs 7.78 Cr is neither the lowest nor the highest print. That context is where the quarterly results turn to the business factors behind the numbers.

Check the Univest Screener for live results data

Key Business Factors This Quarter

Revenue Growth – The quarterly results point to revenue growing 28.5% year on year to Rs 216.97 Cr in the latest quarter. Sudarshan Pharma Industries Q2 Results FY27 therefore start from a larger sales base than the Rs 168.87 Cr recorded a year earlier.

Net Profit Growth – Net profit rose 86.1% year on year to Rs 7.78 Cr, and this gain outpaced the 28.5% increase in revenue. The result is a bottom line that grew at more than three times the pace of the top line.

Margin and Returns – Net profit margin improved to 3.6% from 2.5% in the comparison quarter, while return on equity was 16.74% in FY26. These two measures show how much profit each rupee of sales and equity has produced, which leads into the FY27 outlook.

FY27 Outlook After Sudarshan Pharma Industries Q2 Results

The FY27 outlook starts from the margin and returns picture above. Full-year FY27 results will depend on the subsequent quarters and on disclosed sector conditions, and Sudarshan Pharma Industries Q2 Results FY27 supply the second-quarter base of Rs 216.97 Cr in revenue and Rs 7.78 Cr in net profit.

Investors following this results analysis will want to compare the next quarter with the Rs 7.78 Cr of net profit reported now. Univest keeps the quarterly figures on the Univest app, so any change in net profit can be read against this base, and the risks below show what to watch.

Key Risks to Watch After Sudarshan Pharma Industries Q2 Results FY27

High Debt Level

Debt is high at 1.87 times total assets in FY26. This is a balance sheet fact that investors weigh alongside the Rs 7.78 Cr of net profit reported in the latest quarter and the 16.74% return on equity.

Volatile Quarterly Profit

Quarterly net profit has been volatile, ranging from Rs 4.18 Cr to Rs 10.73 Cr over the last 5 quarters. After Sudarshan Pharma Industries Q2 Results FY27, the 86.12% YoY growth in net profit has to be read against that range.

Thin Profit Margin

Net profit margin was thin at 3.6% in the latest quarter, even after improving from 2.5%. A narrow margin leaves less room if revenue or costs move differently in later quarters.

Download the Univest iOS App or Univest Android App to track quarterly results as they are declared.

Conclusion

Sudarshan Pharma Industries Q2 Results FY27 show revenue of Rs 216.97 Cr and net profit of Rs 7.78 Cr, both higher YoY. The results date of 29 October 2026 brought a margin gain to 3.6%, with net profit growing faster than revenue. These consolidated results make Sudarshan Pharma Industries Q2 Results a useful reference for the quarterly results season. Investors should consult a SEBI-registered advisor before acting.

Frequently Asked Questions on Sudarshan Pharma Industries Q2 Results FY27

What are Sudarshan Pharma Industries Q2 Results FY27?

Ans. Sudarshan Pharma Industries Q2 Results FY27 are the consolidated quarterly results of Sudarshan Pharma Industries for July to September 2026. Their results date was 29 October 2026, as covered in the opening Quick Answer of this article.

What is the results date for Sudarshan Pharma Industries Q2 Results FY27?

Ans. The results date for Sudarshan Pharma Industries Q2 Results FY27 is 29 October 2026, when Sudarshan Pharma Industries reported its July to September 2026 quarter, so every figure in the Financial Highlights table comes from that filing.

What revenue was reported in Sudarshan Pharma Industries Q2 Results FY27?

Ans. Sudarshan Pharma Industries Q2 Results FY27 report revenue of Rs 216.97 Cr, compared with Rs 168.87 Cr in the same quarter last year, which means the Financial Highlights table shows a higher top line.

What net profit was reported in Sudarshan Pharma Industries Q2 Results FY27?

Ans. Sudarshan Pharma Industries Q2 Results FY27 report net profit of Rs 7.78 Cr against Rs 4.18 Cr a year earlier, so the Key Takeaways section treats it as the strongest line of the quarter.

How much YoY growth did revenue show in Sudarshan Pharma Industries Q2 Results FY27?

Ans. Revenue grew 28.48% YoY in Sudarshan Pharma Industries Q2 Results FY27, rising from Rs 168.87 Cr to Rs 216.97 Cr, while the results analysis in the Performance Analysis section compares that pace with net profit.

Did net profit rise or fall in Sudarshan Pharma Industries Q2 Results?

Ans. Net profit rose in Sudarshan Pharma Industries Q2 Results, up 86.12% YoY to Rs 7.78 Cr from Rs 4.18 Cr, and this increase is the main subject of the Performance Analysis section.

What was the net profit margin in Sudarshan Pharma Industries Q2 Results FY27?

Ans. The net profit margin in Sudarshan Pharma Industries Q2 Results FY27 was 3.6% against 2.5% in the comparison quarter, which means profit per rupee of revenue improved, as explained in the Key Business Factors section.

Are Sudarshan Pharma Industries Q2 Results consolidated results or standalone results?

Ans. Sudarshan Pharma Industries Q2 Results are consolidated results, so the revenue of Rs 216.97 Cr and net profit of Rs 7.78 Cr reflect the consolidated basis, as stated in the opening paragraphs of this article.

What business factors shaped Sudarshan Pharma Industries Q2 Results FY27?

Ans. Revenue growth of 28.5% and net profit growth of 86.1% shaped Sudarshan Pharma Industries Q2 Results FY27, alongside a margin of 3.6%, and the Key Business Factors section sets out each of these three points.

What are the key risks after Sudarshan Pharma Industries Q2 Results FY27?

Ans. The key risks after Sudarshan Pharma Industries Q2 Results FY27 are debt of 1.87 times total assets in FY26, volatile quarterly net profit and a thin 3.6% margin, all explained in the Key Risks section.

What is the outlook after Sudarshan Pharma Industries Q2 Results?

Ans. The FY27 outlook after Sudarshan Pharma Industries Q2 Results depends on the subsequent quarters, with the second-quarter base at Rs 216.97 Cr revenue, so the Outlook section frames what to compare next.

Where can I find the complete Sudarshan Pharma Industries Q2 Results FY27 data?

Ans. You can find the complete Sudarshan Pharma Industries Q2 Results FY27 figures in the Financial Highlights table above, and the Univest Screener lists the same quarterly numbers, which supports the results analysis in this article.